Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer^.

IF 1.2 4区医学 Q4 ONCOLOGY

Bladder Cancer Pub Date : 2025-02-24 eCollection Date: 2025-01-01 DOI:10.1177/23523735251319185

Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou, Adam S Feldman, Jared C Foster, Noah M Hahn, Emma Hall, Donna E Hansel, Jean Hoffman-Censits, Ashish M Kamat, Sophia C Kamran, Francesca Khani, Seth P Lerner, Robert Lipman, Bhupinder Mann, David McConkey, James McKiernan, Tracy L Rose, Angela B Smith, Catherine Tangen, Abdul Tawab Amiri, Chana Weinstock, Pamela J West, Matthew I Milowsky, Peter C Black

{"title":"Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup />.","authors":"Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou, Adam S Feldman, Jared C Foster, Noah M Hahn, Emma Hall, Donna E Hansel, Jean Hoffman-Censits, Ashish M Kamat, Sophia C Kamran, Francesca Khani, Seth P Lerner, Robert Lipman, Bhupinder Mann, David McConkey, James McKiernan, Tracy L Rose, Angela B Smith, Catherine Tangen, Abdul Tawab Amiri, Chana Weinstock, Pamela J West, Matthew I Milowsky, Peter C Black","doi":"10.1177/23523735251319185","DOIUrl":null,"url":null,"abstract":"<p><p>The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251319185"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863732/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/23523735251319185","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.

查看原文本刊更多论文

NCI关于下一代非肌肉浸润性膀胱癌临床试验计划会议总结。

国家癌症研究所组织了一场虚拟临床试验计划会议（CTPM），由NCI泌尿生殖系统癌症指导委员会的膀胱癌工作组领导，主题是“定义非肌肉侵袭性膀胱癌（NMIBC）联合治疗的下一代临床试验”。本次会议的目的是加快高风险NMIBC患者临床试验的进展。会议就下一代NMIBC临床试验设计的最佳策略达成了多学科专家共识，并优先考虑联合治疗。制定了两个临床试验概念，以便在国家临床试验网络内实施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bladder Cancer Medicine-Urology

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.

Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer.

Abstract

Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer^.